bioAffinity Technologies, Inc. Warrant
BIAFWStock
$0.10
Market Cap—
P/E—
Div yield—
Beta4.50
Price Chart
Favorite Metrics
Price vs S&P 500 (4W)-66.85%
VGM Score5.22
Industry Peers — R&D — Physical Sciences(15)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BIAFWbioAffinity Technologies, Inc. Warrant | — | — | F | $0.10 |
| IQVIQVIA Holdings Inc. | C | C | B | $210.49 |
| INCYIncyte Genomics Inc | C | A | B | $116.65 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | $537.92 |
| ICLRIcon Plc | C | C | B | $170.00 |
| CRLCharles River Laboratories International, Inc. | D | D | B | $229.16 |
| ABSIAbsci Corporation Common Stock | F | F | A | $8.23 |
| NRCNRC Health Common Stock | D | D | B | $21.94 |
| OABIOmniAb, Inc. Common Stock | D | C | B | $2.04 |
| MXCTMaxCyte, Inc. Common Stock | C | D | B | $1.35 |
| ONMDOneMedNet Corp Class A Common Stock | D | C | C | $0.69 |
About
bioAffinity Technologies develops noninvasive diagnostic tests for early-stage cancer, particularly lung cancer, and targeted cancer therapeutics. Its proprietary CyPath Lung test uses technology that preferentially targets cancer cells to enable early-stage lung cancer detection without invasive procedures. The company addresses a significant clinical need for improved early cancer diagnosis and treatment options.